Brief: Vyant Bio Reports Q3 Results And Provides Strategic And Business Highlights

Vyant Bio

15/11/2022 13:38

Nov 15 (Reuters) - Vyant Bio Inc  VYNT.O :
    * VYANT BIO REPORTS THIRD QUARTER 2022 RESULTS AND PROVIDES
STRATEGIC AND BUSINESS HIGHLIGHTS
    * VYANT BIO INC - $9.4 MILLION OF CASH AND EQUIVALENTS AS OF
SEPTEMBER 30, 2022
    * VYANT BIO INC -  CURRENT CASH BALANCES, NET PROCEEDS FROM
SALE
OF VIVOPHARM EXPECTED TO FUND OPERATIONS UNTIL AT LEAST END OF
2023
    * VYANT BIO INC -  FUTURE PROCEEDS FROM EQUITY LINE OF
CREDIT AND
ATM ARE EXPECTED TO FUND OPERATIONS UNTIL AT LEAST END OF 2023
    * VYANT BIO INC - QTRLY LOSS PER SHARE $0.59

Source text for Eikon:  ID:nGNX1qVBNn 
Further company coverage:  VYNT.O